Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Status Recruiting

Clinical Trial Summary

Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.

Clinical Trial Description

This is a single arm Phase 2 study of pre-operative combination immunotherapy with pembrolizumab and T-VEC given for 6 months prior to complete lymph node dissection for stage 3 resectable cutaneous melanoma with clinically apparent lymph node metastases. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03842943
Study type	Interventional
Source	University of Louisville
Contact	Michael Egger, MD
Phone	502-629-6950
Email	michael.egger@louisville.edu
Status	Recruiting
Phase	Phase 2
Start date	July 3, 2019
Completion date	June 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated	`NCT04042480` - A Study of SGN-CD228A in Advanced Solid Tumors	Phase 1
Recruiting	`NCT04020809` - Neoadjuvant Atezolizumab in Cutaneous Melanoma	Phase 1
Completed	`NCT03620019` - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma	Phase 2
Recruiting	`NCT03767348` - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab	Phase 2
Completed	`NCT03628417` - Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases	N/A
Withdrawn	`NCT05482074` - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2	Phase 2
Recruiting	`NCT05970497` - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT04551352` - A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas	Phase 1
Recruiting	`NCT05544929` - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers	Phase 1
Recruiting	`NCT05628883` - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma	Phase 1
Terminated	`NCT04254107` - A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer	Phase 1
Recruiting	`NCT04830124` - Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6	Phase 2
Recruiting	`NCT03699995` - MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma	N/A
Recruiting	`NCT06319196` - Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma	Phase 2
Recruiting	`NCT05253872` - The MELAcare Study: A New Method for Surveillance of Melanoma Patients	N/A
Recruiting	`NCT04706962` - TH1902 in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04792463` - Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Completed	`NCT00679289` - Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma	Phase 2
Recruiting	`NCT05669430` - A Study of GV20-0251 in Patients With Solid Tumor Malignancies	Phase 1